Israeli drug companies Clal Biotech Industries and BiolineRX sign an agreement for developing and commercializing Clal’s BL-8040, a drug designed for treating acute leukemia and other types of blood cancer. The American FDA has approved the companies’ investigational new drug application.
Related posts
Red Algae Can Treat Wounds And Infections
January 26, 2023
Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023
$6M Investment For “Lettuce Milk” Startup
January 25, 2023
Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments